<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00911482</url>
  </required_header>
  <id_info>
    <org_study_id>08-001493</org_study_id>
    <secondary_id>R01HL067933</secondary_id>
    <nct_id>NCT00911482</nct_id>
  </id_info>
  <brief_title>Production of Free Fatty Acids From Blood Triglycerides</brief_title>
  <official_title>FFA Production From Triglyceride-Rich Lipoproteins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall hypothesis of these studies is that circulating triglycerides, coming primarily&#xD;
      from fat in the diet, are an important source of free fatty acids. Free fatty acids are the&#xD;
      major fat fuel in the body, and when they are elevated in the blood they are thought to raise&#xD;
      the risk of cardiovascular disease by causing insulin resistance (in some cases leading to&#xD;
      diabetes), raising blood pressure, and other effects. The investigator will use sophisticated&#xD;
      methods for tracing triglycerides and free fatty acids in the blood. These methods involve&#xD;
      the administration of low doses of radioactive and stable isotopes of naturally occurring&#xD;
      fats. The studies will determine the contribution of triglycerides to free fatty acids in&#xD;
      normal people and also in people with diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lipid energy is transported in the blood in several forms, including chylomicrons and free&#xD;
      fatty acids (FFA). Chylomicrons are key elements in the absorption and storage of dietary&#xD;
      fat, and also play a role in the pathogenesis of atherosclerosis via the production of&#xD;
      remnant particles, but their role as a direct fuel source has not been explored. FFA are the&#xD;
      major lipid fuel in the body, and increases in their concentration have been shown to cause&#xD;
      insulin resistance, endothelial dysfunction and increases in the production of very low&#xD;
      density lipoproteins. FFA are released into the blood through the action of hormone sensitive&#xD;
      lipase on triglyceride stores in fat cells. Very little is known about the role of&#xD;
      chylomicrons in FFA metabolism, but the potential contribution of chylomicrons to FFA is&#xD;
      considerable, especially in people who consume high fat diets. Initial studies indicate that&#xD;
      in addition to the role of chylomicrons in fat storage, a portion of chylomicron fatty acids&#xD;
      are released as FFA in a process called &quot;spillover&quot;. These studies indicate that the&#xD;
      contribution of chylomicrons to FFA is increased in type 2 diabetes. A study of spillover in&#xD;
      the splanchnic bed found very high rates of splanchnic spillover in overweight and obese&#xD;
      individuals with hypertriglyceridemia. Extremely accurate and precise methods have been&#xD;
      developed by the investigator for the measurement of the concentration and specific activity&#xD;
      of FFA and chylomicron triglyceride fatty acids in plasma. In addition, a tracer method for&#xD;
      accurately determining the kinetics of chylomicrons has been developed. In the proposed&#xD;
      studies, the tracer technique will be used to systematically investigate the contribution of&#xD;
      chylomicrons to total FFA availability. The technique will be applied to normal subjects at&#xD;
      rest and after exercise, as well as subjects with type 2 diabetes mellitus and&#xD;
      hypertriglyceridemia. Specifically, these studies will: 1) determine whether weight loss in&#xD;
      people with type 2 diabetes reduces spillover from chylomicrons; 2) determine whether acute&#xD;
      lowering of FFA with insulin infusion reduces spillover in nondiabetic individuals with&#xD;
      dyslipidemia; 3) determine whether noninsulin-mediated lowering of FFA reduces spillover in&#xD;
      diabetic individuals with dyslipidemia, and 4) determine whether obese, insulin-resistant&#xD;
      individuals have increased spillover in the splanchnic bed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Spillover of free fatty acids from chylomicrons</measure>
    <time_frame>Measured at 1 to 6 days</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Insulin Resistance</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Diabetes/weight loss</arm_group_label>
    <description>12 individuals with type 2 diabetes and hypertriglyceridemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nondiabetic/hypertriglyceridemic</arm_group_label>
    <description>10 insulin resistant nondiabetic individuals with dyslipidemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normotensive/nondiabetic</arm_group_label>
    <description>10 insulin resistant, normotensive, nondiabetic individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin resistant/dyslipidemic</arm_group_label>
    <description>14 insulin resistant nondiabetic individuals with dyslipidemia</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples obtained during the study are stored for lipid analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Volunteers from the region around Rochester, Minnesota who meet the inclusion criteria will&#xD;
        be recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Atherogenic dyslipidemia&#xD;
&#xD;
          -  Obesity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Kidney disease&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Coronary artery disease&#xD;
&#xD;
          -  Retinopathy&#xD;
&#xD;
          -  Neuropathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M. Miles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>May 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2009</study_first_posted>
  <last_update_submitted>November 6, 2012</last_update_submitted>
  <last_update_submitted_qc>November 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2012</last_update_posted>
  <responsible_party>
    <name_title>John M. Miles, MD</name_title>
    <organization>Mayo Foundation</organization>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>FFA</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>Tracers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

